▲

Home  »  History

沿革

1987

April 30, 2024

Dr. Tomio Takeuchi (Representative Director) was elected as MCRF Chairman. Ubenimex (Bestatin ®) was marketed as an anticancer antibiotic. MCRF hosted a symposium marking the 25th anniversary of Institute of Microbial Chemistry. Proceedings: “Horizons on Antibiotic Research,” Ed. by B. D. Davis et al., 1988, Japan Antibiotic Research Association.

1986

April 30, 2024

Dr. Hamao Umezawa, the MCRF founder, passed away at the age of 72 years. He was an internationally respected researcher in the fields of medicine, biology, pharmacology, and organic chemistry. His major achievements include the discovery of kanamycin, bleomycin, and kasugamycin are used to promote human health and welfare.

1985

April 30, 2024

Institute of Chemotherapy was established in Miyamoto, Numazu-shi, Shizuoka to promote chemotherapeutic and immunotherapeutic research.The institute was equipped with modern animal experimentation and radiological facilities.

1982

April 30, 2024

MCRF’s contributions to academic research were officially praised. MCRF was then approved by the Ministry of Health and Welfare and the Ministry of Education, Science, Sports and Culture. MCRF hosted the “Trends in Antibiotic Research” symposium.Proceedings: “Trends in Antibiotic Research,” Ed. by H. Umezawa et al., 1982, Japan Antibiotic Research Association. Aclarubicin was marketed as an anticancer antibiotic.

1981

April 30, 2024

Peplomycin was marketed as an anticancer antibiotic.

1979

April 30, 2024

MCRF hosted a symposium marking the 5th anniversary of the Institute of Bioorganic Chemistry. Proceedings: Jap. J. Antibiot, 32, supplement (1979).

1977

April 30, 2024

MCRF hosted a symposium marking the institute’s 15th anniversary. Proceedings: Jap. J. Antibiot, 30, supplement (1977).

1975

April 30, 2024

Dibekacin was marketed as an antimicrobial antibiotic.

1974

April 30, 2024

Institute of Bioorganic Chemistry was established in Ida, Nakahara-ku, Kawasaki-shi, Kanagawa to study organic synthesis.

1971

April 30, 2024

Dr. Tokuji Ichikawa was elected as MCRF President. Dibekacin, a derivative of kanamycin B, was synthesized and shown to be widely effective against several strains, including Pseudomonas aeruginosa.